Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations
Brigham and Women's Hospital · University Hospital Ulm
Abstract
To assess the prognostic relevance of mutations in the NPM1 gene encoding a nucleocytoplasmic shuttle protein in younger adults with acute myeloid leukemia (AML) and normal cytogenetics, sequencing of NPM1 exon 12 was performed in diagnostic samples from 300 patients entered into 2 consecutive multicenter trials of the AML Study Group (AMLSG). Treatment included intensive double-induction therapy and consolidation therapy with high cumulative doses of high-dose cytarabine. NPM1 mutations were identified in 48% of the patients including 12 novel sequence variants, all leading to a frameshift in the C-terminus of the nucleophosmin 1 (NPM1) protein. Mutant NPM1 was associated with specific clinical, phenotypical,…
Citation impact
- FWCI
- 20.67
- Percentile
- 100%
- References
- 48
Authors
10- KDKonstanze DöhnerCorresponding
Brigham and Women's Hospital, University Hospital Ulm
- RFRichard F. Schlenk
Brigham and Women's Hospital, University Hospital Ulm
- MHMarianne Habdank
Brigham and Women's Hospital, University Hospital Ulm
- CSClaudia Scholl
Brigham and Women's Hospital, University Hospital Ulm
- FGFrank G. Rücker
Brigham and Women's Hospital, University Hospital Ulm
Topics & keywords
- NPM1
- Nucleophosmin
- CEBPA
- Cytogenetics
- Myeloid leukemia
- Biology
- Gene mutation
- Oncology
- Good health and well-being